OS Therapies Inc (NYSE:OSTX) Major Shareholder Shalom Auerbach Sells 16,720 Shares

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 16,720 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total value of $112,692.80. Following the completion of the sale, the insider now owns 2,531,211 shares of the company’s stock, valued at approximately $17,060,362.14. This trade represents a 0.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

OS Therapies Price Performance

NYSE OSTX opened at $2.95 on Monday. The business’s fifty day simple moving average is $3.32. OS Therapies Inc has a fifty-two week low of $1.58 and a fifty-two week high of $7.00.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and set a $20.00 target price on shares of OS Therapies in a research report on Wednesday, January 15th. Maxim Group upped their price objective on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday.

Hedge Funds Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new stake in OS Therapies Inc (NYSE:OSTX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.